---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-001222"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2022-06-09T23:59:59+00:00"
generated_at: "2026-06-25T03:05:34.922479+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexaria licenses DehydraTECH to AnodGen; pre-IND filed for CBD hypertension

## Summary
- Lexaria subsidiary entered 5-year non-exclusive license with AnodGen for DehydraTECH in Europe, UK, Australia, NZ.
- AnodGen will pay royalties on revenues from sales of DehydraTECH-infused powders.
- Pre-IND meeting request filed with FDA for DehydraTECH-CBD for hypertension; target date July 30, 2022.
- IND-enabling development ongoing; Lexaria expects to submit IND in late 2022 or early 2023.
- HYPER-H21-4 study collects 24-hour BP, arterial stiffness, ECG, MRI, biomarkers, and other data.

## SEC filing metadata
- accession: 0001640334-22-001222
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2022-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001222/0001640334-22-001222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001222/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-001222
- JSON: https://secwatch.observer/filing/0001640334-22-001222.json
- Plain text: https://secwatch.observer/filing/0001640334-22-001222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.